Oncolytics Biotech (ONCY) CEO buys 5,050 common shares at $0.96

Rhea-AI Filing Summary

Oncolytics Biotech Inc. chief executive officer Jared Kelly reported an open-market purchase of 5,050 common shares on March 12, 2026 at an average price of $0.96 per share. Following this transaction, he directly owns 114,050 common shares, indicating a modest increase in his personal stake.

Insider Trade Summary

Net Buyer: 5,050 shares ($4,848)

Net Buy 1 txn

Insider Kelly Jared

Role Chief Executive Officer

Bought 5,050 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Shares	5,050	$0.96	$5K

Holdings After Transaction: Common Shares — 114,050 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kelly Jared

(Last) (First) (Middle)

C/O ONCOLYTICS BIOTECH INC.

4350 EXECUTIVE DRIVE, SUITE 325

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ONCOLYTICS BIOTECH INC [ ONCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/12/2026		P		5,050	A	$0.96	114,050	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Kirk Look, Attorney-in-Fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ONCY CEO Jared Kelly report?

Jared Kelly reported buying 5,050 Oncolytics Biotech common shares in the open market. The purchase occurred at an average price of $0.96 per share, modestly increasing his direct ownership position in the company.

At what price did ONCY’s CEO purchase the common shares?

The CEO bought 5,050 common shares at an average price of $0.96. This open-market transaction reflects the actual trading price he paid per share on March 12, 2026, as disclosed in the insider report.

How many ONCY shares does Jared Kelly own after this transaction?

After the reported purchase, Jared Kelly directly owns 114,050 common shares. This total includes the newly acquired 5,050 shares and represents his updated direct equity stake according to the Form 4 disclosure.

Was the ONCY CEO’s transaction a buy or a sell?

The transaction was a buy, specifically an open-market purchase of 5,050 common shares. The filing classifies it under transaction code “P,” which denotes a purchase in the open market or a private transaction.

Did the ONCY Form 4 include any derivative securities activity?

No, the disclosed activity involved only non-derivative common shares. The derivative section shows no remaining options or other derivative positions in this filing, so the reported change relates solely to direct common share ownership.